Abstract | OBJECTIVES: METHODS: RESULTS: The median initial PSA level was 1.6 ng/ml (0-9.5). Each patient demonstrated elevation of at least one of the following markers: carcinoembryonic antigen, CA 19-9, CA15-3 and CA 125 CA. Metastases involved bone in 11 patients (61.1%) - 5 (27.7%) blastic, 2 (11.1%) lytic, and 4 (22.2%) combined - liver in 10 patients (55.5%), lymph nodes in 8 (44.4%), and lung in 6 (33.3%); solitary sites as orbit, skin and spleen were noted as well. A prostatic pelvic mass was detected in 13 patients (72.2%). Of the 12 patients who consented to chemotherapy, 8 (66.6%) achieved an objective response (95% CI, 34. 8-90%), including 1 patient with complete response. Hematoxylin and eosin evaluation revealed two major groups: neuroendocrine tumors, either pure small cell cancer in 6 patients (37.5%) or combined small cell cancer and adenocarcinoma in 8 (50%), and predominant poorly differentiated prostate cancer in 2 (12.5%). Neuroendocrine immunoreactivity was detected in all the specimens. CONCLUSIONS:
|
Authors | A Sella, M Konichezky, D Flex, A Sulkes, J Baniel |
Journal | European urology
(Eur Urol)
Vol. 38
Issue 3
Pg. 250-4
(Sep 2000)
ISSN: 0302-2838 [Print] Switzerland |
PMID | 10940696
(Publication Type: Journal Article)
|
Chemical References |
- Androgens
- Prostate-Specific Antigen
|
Topics |
- Androgens
- Humans
- Male
- Neoplasm Metastasis
- Neoplasm Staging
- Prospective Studies
- Prostate-Specific Antigen
(blood)
- Prostatic Neoplasms
(blood, pathology)
|